about
Chemotherapy versus best supportive care for extensive small cell lung cancerPostprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancerAdvanced EGFR mutation-positive non-small-cell lung cancer: case report, literature review, and treatment recommendationsNonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitorsHigh-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patientsA novel tissue model for angiogenesis: evaluation of inhibitors or promoters in tissue level.First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients.Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer.Resveratrol induces mitochondria-mediated AIF and to a lesser extent caspase-9-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells.Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer.Two microRNA panels to discriminate three subtypes of lung carcinoma in bronchial brushing specimens.Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating centerThe correlation of expression of VEGF and EGFR with SUV of (18)FDG-PET-CT in non-small cell lung cancerN-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell linesAssessing outcomes in palliative chemotherapy.Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo.Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cellsExamination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancerLung cancer. 2: screening and early diagnosis of lung cancerScreening for lung cancer: in pursuit of pre-metastatic disease.Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLCThalidomide: a new anticancer drug?Chinese herbal decoction based on syndrome differentiation as maintenance therapy in patients with extensive-stage small-cell lung cancer: an exploratory and small prospective cohort study.Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.Trastuzumab for the treatment of non-small-cell lung cancer.Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinomaLung tumorigenesis induced by human vascular endothelial growth factor (hVEGF)-A165 overexpression in transgenic mice and amelioration of tumor formation by miR-16.Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapyCombined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell line.Proliferative changes in the bronchial epithelium of former smokers treated with retinoids.Ultrasound guided fine-needle aspiration biopsy of metastases in nonpalpable supraclavicular lymph nodes in lung cancer patientsAntiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathwayA novel taspine analog, HMQ1611, inhibits growth of non-small cell lung cancer by inhibiting angiogenesis.Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.Cancer stem cell hypothesis in thyroid cancer.'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancerGlutamine drives glutathione synthesis and contributes to radiation sensitivity of A549 and H460 lung cancer cell lines.
P2860
Q24240652-E700C023-9C6D-4507-80C5-3136A373A49FQ26829939-06076A35-051D-4D7A-A169-B99B8260EC47Q27021203-545E51AC-EF03-41CA-92F7-DA0877E23AE2Q27693185-7F9C8C9D-03C5-4A47-B77A-A0CF77CA3043Q28256642-1BC6B9D6-1470-44CC-AB83-AB6491C4BA53Q30564436-A78A234E-F79E-415C-9818-EB0B7772464BQ33401434-BD7B7C23-D1AA-4519-932B-B1B790EABA17Q33690276-97BDD17B-97A2-41AB-A6B5-3AFAC1F8438CQ33783059-A5092F1C-747A-4E0D-9EE1-B52670005EECQ33877331-F063C13A-9602-4E04-827C-76D59729CF1CQ34313234-3435B074-7032-44D8-AE5B-91ADC0CB0A6EQ34435850-3964267E-76B8-49FD-A187-9C133810BE76Q34552757-E7E13A3C-FFA8-408C-B192-CBE66A8FA65EQ34589126-3D81B003-BD7D-4E69-9ADC-ABA182032F91Q34631703-F60FE2BB-D1D6-4052-A027-AE1D51B6099DQ34660752-2550080B-73C3-4965-8991-F69B1B89B195Q34678587-FC302F09-099F-4C66-8104-900EB15E402FQ34768400-72BA22E5-A975-428B-A6CF-D6A1E25877BBQ34781725-15F040E6-6ABC-4CB8-9185-C649144E4110Q34786471-38073567-96E1-4C37-9D94-054EE9B80DFDQ35009949-D618812A-1AA1-40FD-A1A4-EAC12B97E9A7Q35037686-EAF9C352-4160-41EA-83F2-1688D7F1A07EQ35050210-90606D7D-7D6F-4A76-B2E0-24534C033EBCQ35164773-7DD1AA57-4F6C-445C-8C5D-C2A63E4E1FCFQ35178092-77B134A1-B136-4DCF-A53E-FC40ED917FE1Q35198447-1359E0D4-8F94-420F-B1A0-F19F07696513Q35590979-A731ABDB-B02E-4B43-BBD9-30FA46576C73Q35667802-91CCC704-5E7A-4794-B655-1EC6EBB8EDEDQ35781614-7199FF95-977F-4306-8CE6-E9FE9F0DEEE7Q35832959-86427CB2-CAF1-4C05-9AF6-A942CE26E2ECQ36071392-B6FCC083-0C1F-44EF-B36B-6E5E9A182149Q36230865-4DC4E92B-023F-4225-908D-F661BBDB6FA6Q36231743-F6109B4F-CD38-43F6-AA0E-291BAD0CCBF2Q36293889-99152F3C-C2E1-4DF4-A26F-3CC2B033A810Q36316939-AEA8624B-2F6D-416B-A0CF-385671DCB737Q36403368-312455CC-AA2D-4209-ABA0-257A0B0F236EQ36403544-7429AEA9-B1BC-45E5-9AA8-EA870E7489D0Q36575963-9B5EE227-C7C5-4BC5-A4E7-7D559356673DQ36610717-A021DB68-C90D-493C-8697-20815E72B8B9Q36622314-6ED71C10-50BF-4FD4-AAAF-7AA29937CDD7
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Lung cancer--time to move on from chemotherapy.
@en
Lung cancer--time to move on from chemotherapy.
@nl
type
label
Lung cancer--time to move on from chemotherapy.
@en
Lung cancer--time to move on from chemotherapy.
@nl
prefLabel
Lung cancer--time to move on from chemotherapy.
@en
Lung cancer--time to move on from chemotherapy.
@nl
P1476
Lung cancer--time to move on from chemotherapy.
@en
P2093
Desmond N Carney
P304
P356
10.1056/NEJM200201103460211
P407
P577
2002-01-01T00:00:00Z